$LLY

Schwab Network on $LLY (Nov 16, 2026)

AI summary · Schwab Network

Eli Lilly is somewhat defensive; continued obesity-drug launches, with Retatrutide/GLP-3 next, may make it a game-changer that eliminates the competition. The speaker says LLY, like Google, has 10 to 20% upside potential, and both can outperform for different reasons and in different scenarios.

Bullish
“Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings”
Schwab NetworkPublished Nov 16 · 3 passages

Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy

Jump to any passage

3 passages

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

So yes, both stocks, for different reasons and in different scenarios, we believe are truly capable of outperforming.

What this channel has said about $LLY

Schwab Network has 7 calls on this stock; only the adjacent ones are shown.

TickerSays